RECRUITING

Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to determine if gentamicin is as effective treatment of acute uncomplicated cystitis (urinary tract infection) using aminoglycosides versus the current standards of care. The current standards of care in our region are often to prescribe a multi-day antibiotic prescription that is taken multiple times per day whereas gentamicin will be a one-time dose in the emergency department. Gentamicin is the medicine being studied.

Official Title

Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting

Quick Facts

Study Start:2022-10-01
Study Completion:2024-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05702762

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * At least 18 years of age, woman, pre-menopausal, non-pregnant with clinical signs of urinary tract infection and nitrite positive urine.
  1. * Contraindications include hypersensitivity to gentamicin or other aminoglycosides.
  2. * Patients younger than 18 years of age.
  3. * Pregnant or post-menopausal patients.
  4. * Patients without symptoms of UTI, nitrite negative urine, or any patient with working diagnosis of complicated UTI such as pyelonephritis or any patient catheterized.
  5. * ANY history of pre-existing renal impairment.
  6. * Patient that has any listed or reports taking ANY nephrotoxic or wit drug-drug interaction medication in the past 7 days (see Appendix 5).
  7. * ANY history of hearing loss, tinnitus, or vertigo.
  8. * ANY patient that has received general anesthesia or neuromuscular blockade in past 7 days.
  9. * Patients with ANY history of neuromuscular disorders including: myasthenia gravis, amyotrophic lateral sclerosis, muscular dystrophy, botulism, congenital myasthenic syndromes, congenital myopathies, myositis, Lambert-Eaton syndrome, mitochondrial myopathy, myotonic dystrophy, neuromyotonia, or peripheral neuropathy.
  10. * Patients with ANY history of thrombocytopenia.
  11. * Patient that has any listed or reports taking ANY anticoagulants in the past 7 days.

Contacts and Locations

Study Contact

Jacob Sieger, DO
CONTACT
6104571345
jsieger@mercy.com
Vincent Peyko, PharmD
CONTACT
3307185919
vjpeyko@mercy.com

Study Locations (Sites)

St. Elizabeth Youngstown Hospital
Youngstown, Ohio, 44501
United States

Collaborators and Investigators

Sponsor: Mercy Health Ohio

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-01
Study Completion Date2024-06-30

Study Record Updates

Study Start Date2022-10-01
Study Completion Date2024-06-30

Terms related to this study

Keywords Provided by Researchers

  • gentamicin
  • single dose antibiotic treatment

Additional Relevant MeSH Terms

  • Urinary Tract Infections